



PHOST'IN THERAPEUTICS JOINS TECHSHARE 2022, EURONEXT'S PAN-EUROPEAN PRE-IPO TRAINING PROGRAM

Montpellier, France – March 2022, 8th

Phost'in Therapeutics (Montpellier, France), a biotech company focused on the discovery and development of N-glycosylation inhibitors for the treatment of cancer and other serious diseases, today joins TechShare 2022, the pan-European pre-IPO educational program of Euronext. For the 7th year, Euronext is renewing its annual support program for growing European Tech companies (digital, cleantech and healthcare) aiming to go public.

This year, more than 120 companies will join the program, including 40 from France, but also 9 other European countries: Germany, Belgium, Spain, France, Ireland, Italy, Norway, Netherlands, Portugal and Switzerland.

Phost'in Therapeutics was selected after a selection process and a presentation to the final jury composed of representatives of TechShare's Selection partners* in France.

As a participant of the TechShare program, **Phost'in Therapeutics** will benefit from support of market experts and already quoted peers to understand the motivations and mechanisms of an IPO. Through a structured training around an academic campus, workshops and individual sessions, participants will be trained in the steps and challenges of an IPO, the building of an equity story and of a company valuation, understanding investors' expectations, good practices in financial communication, corporate governance and post-quotations obligations. The cornerstone of the program is to promote **networking and experience sharing** between participating entrepreneurs, financial market experts and managers of quoted companies.

With more than 750 Tech companies quoted on our markets, Euronext is the leading quotation place for Tech companies in Europe. In 2021, Euronext recorded an ever set high record of 212 listings, with more than 50% of companies from the Tech sector. Euronext Paris hosted a record of 64 quotations in 2021 for nearly 4 billion euros raised, including 54 SMEs-ETIs. Since its launch in 2015, TechShare has welcomed nearly 170 Alumni in France. 10 of these French companies completed an IPO, 6 of them in less than a year, illustrating the market dynamics and growing maturity of the TechShare community.

Karine Chorro, CEO of Phost'in Therapeutics, said: *"We are proud of this selection, and thrilled to take advantage of this opportunity to discuss with quoted companies and the best experts in the ecosystem. This experience should help us to prepare and select the best solutions to ensure our growth, and consolidate our position as a European leader in the Glyco-Immuno-Oncology field, as our first program, the First-In-Class Phox430 is enterin clinical steps. »*

The TechShare 2022 program is also supported by the following institutional partners: AFPC (Association Française des Pôles de Compétitivité, i.e. French association of competitiveness clusters), Bpifrance, CroissancePlus, France Biotech, FranceDigitale, France Fintech, France Invest, GreenUnivers, La French Tech, Réseau PEXE, The Galion Project, WILLA.



About Phost'in Therapeutics

Phost'in Therapeutics is a biotechnology company specialized in the discovery and development of NCE's specifically targeting abnormal pathogenic glycosylation mechanisms. Its PhOx430 program has just filed in Europe for authorization of a multicentric clinical trial for patients suffering of advanced solid cancers. The company also leads upstream research programs in several other diseases using its unique expertise and discovery platform. Spin-off of the academic world, Phost'in disposes, in addition to its own patents, of an exclusive license for two families of academic patents owned by CNRS (Centre National de la Recherche Scientifique), ENSCM (Ecole Nationale Supérieure de Chimie de Montpellier), and the Universities of Montpellier, Sorbonne Paris Nord and Paris Saclay. Based in Montpellier, France, the company was awarded a national Special Prize in the 2014 ILab competition of the French Research Ministry at its creation and has since raised €12m from international funds, with the renewed support of bpifrance, LifeScience cluster Eurobiomed, Region Occitanie and Montpellier Med Vallée. www.phostin.com

About Euronext

Euronext is the leading pan-European market infrastructure, connecting European economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With close to 2,000 listed equity issuers and around €6.9 trillion in market capitalisation as of end December 2021, it has an unmatched blue chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe's leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. The Group provides a multi-asset clearing house through Euronext Clearing, and custody and settlement services through Euronext Securities central securities depositories in Denmark, Italy, Norway and Portugal. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs. Euronext provides custody and settlement services through central securities depositories in Denmark, Italy, Norway and Portugal. For the latest news, follow us on Twitter (twitter.com/euronext) and LinkedIn (linkedin.com/euronext).

Contact:

Karine Chorro, CEO

contact@phostin.com

Phost'in Therapeutics, 104 rue de la Galera, 34 090 Montpellier FRANCE